Endpoint Determination Study Protocol

• ClinicalTrials.gov Identifier: NCT03459482
• Recruitment Status: Completed
• First Posted: March 9, 2018
• Last Update Posted: March 18, 2022
• Sponsor: Biomerica
• Information provided by (Responsible Party): Biomerica

Study Description

Brief Summary:

This study is designed to evaluate the most applicable endpoints for evaluation of the Biomerica InFoods® IBS product.

Condition or disease	Intervention/treatment	Phase
Irritable Bowel Syndrome	Other: Food Elimination Diet	Not Applicable

Detailed Description:

The objective of this Endpoint Determination Study is to address key elements regarding a proposed larger clinical study design:

1. Comparing different potential primary outcome measures
2. Demonstrating that an exclusionary diet as determined by elevated IgG levels using the Biomerica InFoods® IBS Test is associated with alleviation of IBS symptoms
3. Demonstrating the ability to mask the sham diet
4. Demonstrating the safety of the exclusionary diet

Subjects' diets will be based on the results of the Biomerica, InFoods® IBS Test.

Immunoglobulin G (IgG) levels above a certain threshold are considered a positive response against a specific food or foods. It is expected that severity of symptoms of IBS will decrease when foods that generate a positive immune response in the Biomerica InFoods® IBS test are eliminated from the diet of the IBS patient.

The Endpoint Determination Study format will be a double-blinded randomized controlled clinical study enrolling subjects at two trial sites within the United States and designed to evaluate the use of IgG antibody guided dietary restrictions, based on the Biomerica InFoods® IBS Test, in the management of patients diagnosed with Irritable Bowel Syndrome (IBS).

The 2 sites will enroll approximately equal numbers of subjects. The target for each site is a minimum of 30 subjects in each classification: IBS with diarrhea [IBS-D], IBS with constipation [IBS-C] and IBS mixed [IBS-M] for a minimum of 90 patients per site, 180 total subjects for this study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 556 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Parallel Design
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: Endpoint Determination Study for An Antibody Guided Dietary Restriction Trial Using Biomerica InFoods® IBS Test in Patients With a Previous Diagnosis of Irritable Bowel Syndrome (IBS)
• Actual Study Start Date: June 21, 2018
• Actual Primary Completion Date: December 31, 2021
• Actual Study Completion Date: December 31, 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group 1 - True Food Elimination Diet; Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.	Other: Food Elimination Diet; Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms
Sham Comparator: Group 2 - Sham Food Elimination Diet; Group 2 (control group): Subjects will be given a "Sham" elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.	Other: Food Elimination Diet; Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms

Outcome Measures

Primary Outcome Measures :

1. Change in the IBS-API - Abdominal Pain Intensity. The IBS-API is being assessed daily from enrollment (baseline) to study completion; total 10 weeks [ Time Frame: Daily for 10 weeks ]
   Abdominal pain intensity will be measured daily using an 11-point (0-10) numeric rating scale (NRS) that asks subjects to rate their worst abdominal pain over the past 24-hours.

Eligibility Criteria

• Ages Eligible for Study: 21 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• 21 years old or older.
• Able to read and understand English.
• Have access to a computer and/or cell phone access for Electronic Data Capture (EDC)
• Meets Rome III or Rome IV Diagnostic Criteria for IBS
• Respond "No" to IBS Adequate Relief (IBS-AR) in the past week at the screening Visit#1.
• Score between ≥ 3 and <7.5 on the Abdominal Pain Intensity Assessment (IBS_API) based on a weekly average of worst daily (in past 24 hours) abdominal pain on a 0 to 10 point scale.
• A positive IgG antibody response for at least one food in the Biomerica InFoods® IBS panel
• Patients who are on stable (> 3 months) doses of medications or treatments for their IBS (e.g., probiotics, fiber, Viberzi, Linzess, Amitiza, Alosetron, Plecanatide, anticholinergics, antidepressants, Zofran bile acid sequestrants, or anti-diarrheals) will be allowed to continue their medications as long as no change in treatment is planned for the duration of the study and no dose adjustment is made during the duration of the study.
• Willing to follow a food elimination diet.

Exclusion Criteria:

• Cannot use EDC system due to no cell phone and no computer access
• Unable to provide consent.
• Pregnant or breastfeeding
• Does not qualify for a diagnosis of IBS by Rome III or IV Diagnostic Criteria
• Diagnosed IBS, but an IBS-API score of <3.0 and >7.5
• Patients who have used Rifaximin in the past 3 months
• Patients engaged in another type of diet therapy i.e. FODMAP
• Patients which physicians are anticipating starting a new medication, change in dosage, diet or other treatment for IBS during the study
• Chronic pain from other conditions besides IBS
• Current or previous use of narcotic medications within past 3 months
• History of prior GI surgery except for cholecystectomy or appendectomy.

Contacts and Locations

Locations

United States, Arizona

Mayo Clinic

Scottsdale, Arizona, United States, 85259

United States, Florida

Mayo Clinic

Jacksonville, Florida, United States, 32224

United States, Illinois

Family Medicine Specialists

Wauconda, Illinois, United States, 60084

United States, Massachusetts

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States, 02215

United States, Michigan

University of Michigan Health System

Ann Arbor, Michigan, United States, 48109-5362

United States, Texas

Houston Methodist Research Institute

Houston, Texas, United States, 77030

UT Health

Houston, Texas, United States, 77030

Gastroenterology Research of San Antonio

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Biomerica

Investigators

• Principal Investigator: William D Chey, MD; University of Michigan
• Principal Investigator: Anthony J Lembo, MD; Beth Israel Deaconess Medical Center (Harvard)

More Information

• Responsible Party: Biomerica
• ClinicalTrials.gov Identifier: NCT03459482
• Other Study ID Numbers: EPT-InF24-001
• First Posted: March 9, 2018
• Last Update Posted: March 18, 2022
• Last Verified: March 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No
• Plan Description: It is not yet known if there will be a plan to make IPD available.

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Irritable Bowel Syndrome; Syndrome; Disease; Pathologic Processes; Colonic Diseases, Functional; Colonic Diseases; Intestinal Diseases; Gastrointestinal Diseases; Digestive System Diseases